JoVE Logo
Faculty Resource Center

Sign In

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL

DOI :

10.3791/2801-v

7:18 min

April 11th, 2011

April 11th, 2011

14,992 Views

1Immunology Graduate Program, Johns Hopkins University, 2Department of Internal Medicine, Far-Eastern Memorial Hospital, 3Department of Pathology, Johns Hopkins University, 4Institute of Cell Engineering, Johns Hopkins University

A new DC independent method for induction and expansion of antigen-specific T cells is described. HLA A2-Ig based artificial Antigen Presenting Cells (aAPC) are loaded with HLA-A2 restricted peptides to efficiently expand CTL of diverse antigen specificity. This technology holds great potential for CTL-based adoptive immunotherapy.

Tags

HLA Ig

-- Views

Related Videos

article

Antigen Specific In Vivo Killing Assay using CFSE Labeled Target Cells

article

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

article

Expansion, Purification, and Functional Assessment of Human Peripheral Blood NK Cells

article

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate

article

Artificial Antigen Presenting Cell (aAPC) Mediated Activation and Expansion of Natural Killer T Cells

article

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

article

Assessing the Innate Sensing of HIV-1 Infected CD4+ T Cells by Plasmacytoid Dendritic Cells Using an Ex vivo Co-culture System.

article

Killer Artificial Antigen Presenting Cells (KaAPC) for Efficient In Vitro Depletion of Human Antigen-specific T Cells

article

Lymphocyte Isolation from Human Skin for Phenotypic Analysis and Ex Vivo Cell Culture

article

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved